Online citations, reference lists, and bibliographies.
← Back to Search

Vaccination Of Mice With A Modified Vaccinia Ankara (MVA) Virus Expressing The African Horse Sickness Virus (AHSV) Capsid Protein VP2 Induces Virus Neutralising Antibodies That Confer Protection Against AHSV Upon Passive Immunisation.

Eva Calvo-Pinilla, Francisco de la Poza, S. Gubbins, P. Mertens, J. Ortego, J. Castillo-Olivares
Published 2014 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
In previous studies we showed that a recombinant Modified Vaccinia Ankara (MVA) virus expressing the protein VP2 of AHSV serotype 4 (MVA-VP2) induced virus neutralising antibodies in horses and protected interferon alpha receptor gene knock-out mice (IFNAR-/-) against challenge. We continued these studies and determined, in the IFNAR-/- mouse model, whether the antibody responses induced by MVA-VP2 vaccination play a key role in protection against AHSV. Thus, groups of mice were vaccinated with wild type MVA (MVA-wt) or MVA-VP2 and the antisera from these mice were used in a passive immunisation experiment. Donor antisera from (a) MVA-wt; (b) MVA-VP2 vaccinated; or (c) MVA-VP2 vaccinated and AHSV infected mice, were transferred to AHSV non-immune recipient mice. The recipients were challenged with virulent AHSV together with MVA-VP2 vaccinated and MVA-wt vaccinated control animals and the levels of protection against AHSV-4 were compared between all these groups. The results showed that following AHSV challenge, mice that were passively immunised with MVA-VP2 vaccinated antisera were highly protected against AHSV disease and had lower levels of viraemia than recipients of MVA-wt antisera. Our study indicates that MVA-VP2 vaccination induces a highly protective humoral immune response against AHSV.
This paper references
10.1016/0042-6822(91)90808-O
A comparison of the nucleotide sequences of cognate NS2 genes of three different orbiviruses.
V. van Staden (1991)
10.1099/0022-1317-81-4-993
Identification of antigenic regions on VP2 of African horsesickness virus serotype 3 by using phage-displayed epitope libraries.
L. Bentley (2000)
Recombinant baculovirus-synthesized African horsesickness virus ( AHSV ) outer-capsid protein VP 2 provides protection against virulent AHSV challenge
L. H. (2007)
50 % end - point calculation
V. Manole
10.1016/0264-410X(94)90052-3
Further studies on the efficacy of an inactivated African horse sickness serotype 4 vaccine.
J. A. House (1994)
10.1016/0147-9571(94)90046-9
African horse sickness virus structure.
P. Roy (1994)
10.1371/journal.pone.0034735
Multiserotype Protection Elicited by a Combinatorial Prime-Boost Vaccination Strategy against Bluetongue Virus
Eva Calvo-Pinilla (2012)
10.1099/0022-1317-77-9-2053
Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge.
P. Roy (1996)
10.1099/0022-1317-77-6-1211
Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7.
J. Martínez-Torrecuadrada (1996)
10.1006/VIRO.1995.1355
Identification of a linear neutralization domain in the protein VP2 of African horse sickness virus.
J. Martínez-Torrecuadrada (1995)
10.1016/j.vetimm.2012.01.016
Virus-specific CD8⁺ T-cells detected in PBMC from horses vaccinated against African horse sickness virus.
Alri Pretorius (2012)
Immune responses in a horse inoculated with the VP2 gene of African horsesickness virus.
M. Romito (1999)
10.1006/VIRO.1993.1537
Neutralizing epitopes of African horsesickness virus serotype 4 are located on VP2.
T. G. Burrage (1993)
R: A language and environment for statistical computing.
R. Team (2014)
10.1371/journal.pone.0005997
Induction of Antibody Responses to African Horse Sickness Virus (AHSV) in Ponies after Vaccination with Recombinant Modified Vaccinia Ankara (MVA)
R. Chiam (2009)
10.1371/journal.pone.0005171
Establishment of a Bluetongue Virus Infection Model in Mice that Are Deficient in the Alpha/Beta Interferon Receptor
Eva Calvo-Pinilla (2009)
African horse-sickness killed-virus tissue culture vaccine.
Y. Ozawa (1966)
10.1371/journal.pone.0016503
A Modified Vaccinia Ankara Virus (MVA) Vaccine Expressing African Horse Sickness Virus (AHSV) VP2 Protects Against AHSV Challenge in an IFNAR −/− Mouse Model
J. Castillo-Olivares (2011)
10.1016/j.vetimm.2012.06.009
An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses.
H. El Garch (2012)
10.1128/JVI.00517-12
Structural Insight into African Horsesickness Virus Infection
Violeta Manole (2012)
10.1007/BF02239981
Observations on antibody levels associated with active and passive immunity to African horse sickness
N. Blackburn (2005)
10.1016/j.vaccine.2009.05.044
Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus.
A. Guthrie (2009)
10.1006/VIRO.1996.0304
Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4.
M. Stone-Marschat (1996)
10.1371/journal.pone.0070197
Ns1 Is a Key Protein in the Vaccine Composition to Protect Ifnar(−/−) Mice against Infection with Multiple Serotypes of African Horse Sickness Virus
Francisco de la Poza (2013)
10.1136/vr.98.10.204-b
African horse sickness
J. Parker (1976)
10.1051/VETRES:2004021
African horse sickness.
P. Mellor (1998)
10.1371/journal.pone.0025697
Detection of a Fourth Orbivirus Non-Structural Protein
Mourad Belhouchet (2011)



This paper is referenced by
10.1128/JVI.02183-14
A Synthetic Biology Approach for a Vaccine Platform against Known and Newly Emerging Serotypes of Bluetongue Virus
Sandro Filipe Nunes (2014)
10.1016/j.coviro.2020.06.003
Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design
Eva Calvo-Pinilla (2020)
Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus ( AHSV ) VP 2
Eva Calvo-Pinilla (2015)
10.1016/j.antiviral.2015.01.009
Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge
Eva Calvo-Pinilla (2015)
10.4172/1745-7580.1000135
Immunoinformatics Prediction of Peptide-Based Vaccine Against AfricanHorse Sickness Virus
M. Abdelbagi (2017)
10.1016/j.imbio.2015.09.002
Immune gene expression profiling of PBMC isolated from horses vaccinated with attenuated African horsesickness virus serotype 4.
Alri Pretorius (2016)
10.1016/j.vaccine.2018.03.003
African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform.
P. V. van Rijn (2018)
10.1016/j.virusres.2015.08.005
Identification of CD8 T cell epitopes in VP2 and NS1 proteins of African horse sickness virus in IFNAR(-/-) mice.
Francisco de la Poza (2015)
10.1016/j.vaccine.2018.05.044
Diagnostic DIVA tests accompanying the Disabled Infectious Single Animal (DISA) vaccine platform for African horse sickness.
P. V. van Rijn (2018)
10.1016/j.vaccine.2014.04.036
Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge
Berta Alberca (2014)
10.1111/pbi.12783
Immunogenicity of plant‐produced African horse sickness virus‐like particles: implications for a novel vaccine
S. Dennis (2018)
10.1016/j.jviromet.2017.10.003
Strategies to obtain multiple recombinant modified vaccinia Ankara vectors. Applications to influenza vaccines.
Andrea Barbieri (2018)
10.3390/v11010035
Modeling Arboviral Infection in Mice Lacking the Interferon Alpha/Beta Receptor
A. Marín-López (2019)
Against Known and Newly Emerging 1 Serotypes of Bluetongue Virus 2 3
Sandro Filipe Nunes (2014)
10.1016/j.vaccine.2018.09.065
A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model
Mine Aksular (2018)
10.1016/j.antiviral.2018.04.015
The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host
Eva Calvo-Pinilla (2018)
10.1007/978-1-4939-3008-1_9
Generation of Recombinant Modified Vaccinia Virus Ankara Encoding VP2, NS1, and VP7 Proteins of Bluetongue Virus.
A. Marín-López (2016)
10.1016/j.vaccine.2017.04.005
Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.
N. M. Manning (2017)
Desarrollo de vacunas recombinantes marcadoras multiserotipo frente al virus de la lengua azul
Alejandro Marín López (2017)
10.1016/j.vetmic.2014.10.006
Study of the virulence of serotypes 4 and 9 of African horse sickness virus in IFNAR(-/-), Balb/C and 129 Sv/Ev mice.
Maria Ana de la Grandière (2014)
10.1128/JVI.01052-15
VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV
S. V. D. van de Water (2015)
10.1111/evj.13353
African horse sickness in Thailand: Challenges of controlling an outbreak by vaccination.
Javier Castillo-Olivares (2020)
10.1016/j.virusres.2016.04.007
African horse sickness virus serotype 4 antigens, VP1-1, VP2-2, VP4, VP7 and NS3, induce cytotoxic T cell responses in vitro.
F E Faber (2016)
10.4102/ojvr.v84i1.1313
B-cell epitopes of African horse sickness virus serotype 4 recognised by immune horse sera
E. M. Mathebula (2017)
10.3390/v11090844
African Horse Sickness: A Review of Current Understanding and Vaccine Development
S. J. Dennis (2019)
Semantic Scholar Logo Some data provided by SemanticScholar